Tim Opler, Flame Biosciences co-CEO
Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences
Flame Biosciences gave up on its IL-1ß inhibitor last fall after Novartis’ asset in the class failed multiple studies. To save itself, the biotech is selling to Leap Therapeutics.
Not in the foreground of the picture? The IL-1ß inhibitor, known as FL-101. Instead, Leap’s buyout focuses on anti-Claudin18.2 antibody FL-301 and two preclinical antibodies, including an anti-Claudin18.2/CD137 bispecific and anti-GDF15 monoclonal.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters